SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(8 sites)

United States

The House Institute, Los Angeles, California

ENT and Allergy Associates of Florida, Boca Raton, Florida

University of Miami, Miami, Florida

Northwell Health, New Hyde Park, New York

ENT and Allergy Associates, LLP, New York, New York

Medical University of South Carolina, Charleston, South Carolina

University of Texas Southwestern, Dallas, Texas

Medical College of Wisconsin, Milwaukee, Wisconsin